Related Research Articles
Lassa fever, also known as Lassa hemorrhagic fever (LHF), is a type of viral hemorrhagic fever caused by the Lassa virus. Many of those infected by the virus do not develop symptoms. When symptoms occur they typically include fever, weakness, headaches, vomiting, and muscle pains. Less commonly there may be bleeding from the mouth or gastrointestinal tract. The risk of death once infected is about one percent and frequently occurs within two weeks of the onset of symptoms. Of those who survive, about a quarter have hearing loss, which improves within three months in about half of these cases.
Rift Valley fever (RVF) is a viral disease of humans and livestock that can cause mild to severe symptoms. The mild symptoms may include: fever, muscle pains, and headaches which often last for up to a week. The severe symptoms may include: loss of sight beginning three weeks after the infection, infections of the brain causing severe headaches and confusion, and bleeding together with liver problems which may occur within the first few days. Those who have bleeding have a chance of death as high as 50%.
Marburg virus disease is a viral hemorrhagic fever in humans and primates caused by either of the two Marburgviruses: Marburg virus (MARV) and Ravn virus (RAVV). Its clinical symptoms are very similar to those of Ebola virus disease (EVD).
A biological hazard, or biohazard, is a biological substance that poses a threat to the health of living organisms, primarily humans. This could include a sample of a microorganism, virus or toxin that can adversely affect human health. A biohazard could also be a substance harmful to other animals.
Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses in which fever and hemorrhage are caused by a viral infection. VHFs may be caused by five distinct families of RNA viruses: the families Filoviridae, Flaviviridae, Rhabdoviridae, and several member families of the Bunyavirales order such as Arenaviridae, and Hantaviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in many cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, while others, such as Ebola virus, can cause severe, life-threatening disease.
The United States Army Medical Research Institute of Infectious Diseases is the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare. It is located on Fort Detrick, Maryland and is a subordinate lab of the U.S. Army Medical Research and Development Command (USAMRDC), headquartered on the same installation.
Argentinian mammarenavirus, better known as the Junin virus or Junín virus (JUNV), is an arenavirus in the Mammarenavirus genus that causes Argentine hemorrhagic fever (AHF). The virus took its original name from the city of Junín, around which the first cases of infection were reported, in 1958.
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.
Lisa Ellen Hensley is the Associate Director of Science at the Office of the Chief Scientist, National Institute of Allergy and Infectious Disease Integrated Research Facility in Frederick, Maryland. She was previously a civilian microbiologist in the virology division of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Hensley is one of the premier researchers of some of the world's most dangerous infections, including Ebola hemorrhagic fever, Lassa fever, the coronavirus diseases Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and smallpox. She has been involved in research uncovering critical mechanisms in the pathogenesis of hemorrhagic fever viruses, and has used those discoveries to develop candidate therapeutic drugs for their treatment.
Marburg virus is a hemorrhagic fever virus of the Filoviridae family of viruses and a member of the species Marburg marburgvirus, genus Marburgvirus. Marburg virus (MARV) causes Marburg virus disease in primates, a form of viral hemorrhagic fever. The virus is considered to be extremely dangerous. The World Health Organization (WHO) rates it as a Risk Group 4 Pathogen. In the United States, the NIH/National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent. It is also listed as a biological agent for export control by the Australia Group.
The United States biological defense program—in recent years also called the National Biodefense Strategy—refers to the collective effort by all levels of government, along with private enterprise and other stakeholders, in the United States to carry out biodefense activities.
Oyewale Tomori is a Nigerian professor of virology, educational administrator, and former vice chancellor of Redeemer's University.
Robert Ellis Shope was an American virologist, epidemiologist and public health expert, particularly known for his work on arthropod-borne viruses and emerging infectious diseases. He discovered more novel viruses than any person previously, including members of the Arenavirus, Hantavirus, Lyssavirus and Orbivirus genera of RNA viruses. He researched significant human diseases, including dengue, Lassa fever, Rift Valley fever, yellow fever, viral hemorrhagic fevers and Lyme disease. He had an encyclopedic knowledge of viruses, and curated a global reference collection of over 5,000 viral strains. He was the lead author of a groundbreaking report on the threat posed by emerging infectious diseases, and also advised on climate change and bioterrorism.
The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID).
Jean-Paul Joseph Gonzalez is a French virologist. He graduated from the Medical School of Bordeaux University France.
Ho Wang Lee was a South Korean physician, epidemiologist, and virologist. He was the first person in the history of medicine to be the one chiefly responsible for all 3 of the following steps: (1) discovery of the virus causing a human disease, (2) development of a method of diagnosis for the disease, and (3) development of a vaccine against the disease.
A notifiable disease is one which the law requires to be reported to government authorities.
Daniel R. Lucey is an American physician, researcher, senior scholar and adjunct professor of infectious diseases at Georgetown University, and a research associate in anthropology at the Smithsonian National Museum of Natural History, where he has co-organised an exhibition on eight viral outbreaks.
Heinz (Heinrich) Ulrich Feldmann is a German-American virologist who currently serves as the chief of the laboratory of virology at Rocky Mountain Laboratories, NIAID and heads the Disease Modelling and Transmission section. His research focuses on highly pathogenic viruses that require strict biocontainment, including those that cause viral hemorrhagic fever such as Ebola and Lassa. He has been responsible for the development of timely viral countermeasures including the rVSV-ZEBOV vaccine (Ervebro), development of vaccines and drugs against SARS-CoV-2, and epidemiology of SARS-CoV.
Pragya D. Yadav is an Indian scientist at the ICMR-National Institute of Virology (NIV), who is known for her research contributions in the field of communicable diseases and highly pathogenic viral infections, such as Crimean–Congo hemorrhagic fever (CCHF), Nipah, Ebola, leading to improvising national public health surveillance policy for interventions and management. Yadav is among the scientists who detected the first three COVID-19 pandemic cases in India. She headed the team that developed Covaxin, the first indigenous COVID-19 vaccine in India
References
- Peters, C. J. and Mark Olshaker (1998), Virus Hunter: Thirty Years of Battling Hot Viruses Around the World, Random House.
